China Bio-Med Regeneration Technology Limited (“China Bio-Med”) （Previously named as BM Intelligence International Limited）was incorporated in the Cayman Islands and was listed at the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited at 18th July 2001 with Stock Code 8158. Through Shaanxi Aierfu Activtissue Engineering Company Limited (“Shaanxi Aierfu Activtissue”) which is 87.68% held by its wholly owned subsidiary - FD (H) Investments Limited, China Bio-Med mainly engages in the research and development as well as production of tissue engineering products.
Incorporated in PRC since 2002，Shaanxi Aierfu Activtissue is the first private high-tech company in China specializing in the R&D of tissue engineering in medical regeneration field. The research and development of tissue engineering products and its commercialization is designated as one of the pivotal projects by China Central Government ‘‘863 High-Tech Program’’ from the Ministry of Science & Technology. Shaanxi Aierfu Activtissue’s major product, the Tissue Engineering Skin (“ActivSkin”) is the achievement of the close collaboration between Shaanxi Aierfu Activtissue and the Fourth Military Medical University in China. The ActivSkin has a similar structure to the natural normal human skin. It can be applied in different burns treatment and in treatment of ulcers, traumas and other skin defects. All equipments of the plant for production of the ActivSkin have already in place and the trial operation of the new plant has been carried out year 2010.
Another major product is “Acellular Cornea”under the research and development of Shaanxi AiNear Cornea Engineering Company Limited, a subsidiary of Shaanxi Aierfu Activtissue. The development in Shaanxi AiNear’s tissue engineering in cornea when success will definitely meet the demand of cornea in the society, making a breakthrough in traditional ophthalmology treatments and creating both economic benefits and social efficiency. Acellular Cornea has stepped into the stage of clinical trials and it is expected that all clinical trials will be completed soon.
Other product, namely “Selective Acellular Porcine Skin”, is researched and developed by Shaanxi AiBosin Bio-Engineering Company Limited, another subsidiary of Shaanxi Aierfu Activtissue. Selective Acellular Porcine Skin is mainly used for large-area burns and ulcers, and currently is already access to the clinical trials.
Apart from existing self-developed products, the Group has always been actively investigating and looking for opportunities elsewhere. Recently, the Group has entered into a framework agreement with Shaanxi Reshine Biotech Company Ltd (“Reshine Biotech”). Reshine Biotech is specializing in R&D of tissue engineering series products for tissue defects recovery and cosmetic reconstruction. While their tissue engineering projects remain premature, the Group sees potentials there and the signing of the framework agreement is to ensure us to have the pre-emption rights for their projects.
Shaanxi Aierfu Activtissue is a company incorporated in PRC since 2002. Its principal business activities are R&D of medical, biological and tissue engineering. The research and development of tissue engineering products and its commercialization is designated as one of the pivotal projects by China Central Government ‘‘863 High-Tech Program’’ from the Ministry of Science & Technology.
Shaanxi Aierfu Activtissue major products include the “ActivSkin” and “Acellular Cornea”. Although “ActivSkin” could be put into commercial production, in order to widen its application on indications, especially during the recovery stage of diabetic foot treatment, Shaanxi Aierfu Activtissue has enrolled more cases for “clinical trial for increase indication as at the end of Oct 2010, 67 cases with four hospitals, including Air Force General Hospital, have been enrolled. Shaanxi Aierfu Activtissue strives to complete all clinical trials by next year. Meanwhile, other products such as “Acellular Cornea” and “ Selective Acellular Porcine Skin” are already access to clinical stage.
In response to the industrialization of tissue engineering skin products, Shaanxi Aierfu Activtissue New Research and Production Center In Xian has been complete and trial operation has commenced last year.
Address:Room 3101-3105, 31/F, Dah Sing Financial Centre, 108 Gloucester Road, Wanchai, Hong Kong,
Telephone:(852) 3966 8388
fax:(852) 2802 0026
Email:[email protected]
Website :http://www.bmregeneration.com/
![]()
|
